NBS1 expression as a prognostic marker in uveal melanoma

Justis P. Ehlers, J. William Harbour

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: Up to half of uveal melanoma patients die of metastatic disease. Treatment of the primary eye tumor does not improve survival in high-risk patients due to occult micrometastatic disease, which is present at the time of eye tumor diagnosis but is not detected and treated until months to years later. Here, we use microarray gene expression data to identify a new prognostic marker. Experimental Design: Microarray gene expression profiles were analyzed in 25 primary uveal melanomas. Tumors were ranked by support vector machine (SVM) and by cytologic severity. Nbs1 protein expression was assessed by quantitative immunohistochemistry in 49 primary uveal melanomas. Survival was assessed using Kaplan-Meier life-table analysis. Results: Expression of the Nijmegen breakage syndrome (NBS1) gene correlated strongly with SVM and cytologic tumor rankings (P < 0.0001). Further, immunohistochemistry expression of the Nbs1 protein correlated strongly with both SVM and cytologic rankings (P < 0.0001). The 6-year actuarial survival was 100% in patients with low immunohistochemistry expression of Nbs1 and 22% in those with high Nbs1 expression (P = 0.01). Conclusions: NBS1 is a strong predictor of uveal melanoma survival and potentially could be used as a clinical marker for guiding clinical management.

Original languageEnglish
Pages (from-to)1849-1853
Number of pages5
JournalClinical Cancer Research
Volume11
Issue number5
DOIs
StatePublished - Mar 1 2005
Externally publishedYes

Fingerprint

Survival
Immunohistochemistry
Neoplasms
Nijmegen Breakage Syndrome
Life Tables
Transcriptome
Proteins
Research Design
Biomarkers
Gene Expression
Uveal melanoma
Genes
Support Vector Machine
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

NBS1 expression as a prognostic marker in uveal melanoma. / Ehlers, Justis P.; William Harbour, J.

In: Clinical Cancer Research, Vol. 11, No. 5, 01.03.2005, p. 1849-1853.

Research output: Contribution to journalArticle

@article{51475c4b1060454c866b6aaf0a577175,
title = "NBS1 expression as a prognostic marker in uveal melanoma",
abstract = "Purpose: Up to half of uveal melanoma patients die of metastatic disease. Treatment of the primary eye tumor does not improve survival in high-risk patients due to occult micrometastatic disease, which is present at the time of eye tumor diagnosis but is not detected and treated until months to years later. Here, we use microarray gene expression data to identify a new prognostic marker. Experimental Design: Microarray gene expression profiles were analyzed in 25 primary uveal melanomas. Tumors were ranked by support vector machine (SVM) and by cytologic severity. Nbs1 protein expression was assessed by quantitative immunohistochemistry in 49 primary uveal melanomas. Survival was assessed using Kaplan-Meier life-table analysis. Results: Expression of the Nijmegen breakage syndrome (NBS1) gene correlated strongly with SVM and cytologic tumor rankings (P < 0.0001). Further, immunohistochemistry expression of the Nbs1 protein correlated strongly with both SVM and cytologic rankings (P < 0.0001). The 6-year actuarial survival was 100{\%} in patients with low immunohistochemistry expression of Nbs1 and 22{\%} in those with high Nbs1 expression (P = 0.01). Conclusions: NBS1 is a strong predictor of uveal melanoma survival and potentially could be used as a clinical marker for guiding clinical management.",
author = "Ehlers, {Justis P.} and {William Harbour}, J.",
year = "2005",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-04-2054",
language = "English",
volume = "11",
pages = "1849--1853",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - NBS1 expression as a prognostic marker in uveal melanoma

AU - Ehlers, Justis P.

AU - William Harbour, J.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Purpose: Up to half of uveal melanoma patients die of metastatic disease. Treatment of the primary eye tumor does not improve survival in high-risk patients due to occult micrometastatic disease, which is present at the time of eye tumor diagnosis but is not detected and treated until months to years later. Here, we use microarray gene expression data to identify a new prognostic marker. Experimental Design: Microarray gene expression profiles were analyzed in 25 primary uveal melanomas. Tumors were ranked by support vector machine (SVM) and by cytologic severity. Nbs1 protein expression was assessed by quantitative immunohistochemistry in 49 primary uveal melanomas. Survival was assessed using Kaplan-Meier life-table analysis. Results: Expression of the Nijmegen breakage syndrome (NBS1) gene correlated strongly with SVM and cytologic tumor rankings (P < 0.0001). Further, immunohistochemistry expression of the Nbs1 protein correlated strongly with both SVM and cytologic rankings (P < 0.0001). The 6-year actuarial survival was 100% in patients with low immunohistochemistry expression of Nbs1 and 22% in those with high Nbs1 expression (P = 0.01). Conclusions: NBS1 is a strong predictor of uveal melanoma survival and potentially could be used as a clinical marker for guiding clinical management.

AB - Purpose: Up to half of uveal melanoma patients die of metastatic disease. Treatment of the primary eye tumor does not improve survival in high-risk patients due to occult micrometastatic disease, which is present at the time of eye tumor diagnosis but is not detected and treated until months to years later. Here, we use microarray gene expression data to identify a new prognostic marker. Experimental Design: Microarray gene expression profiles were analyzed in 25 primary uveal melanomas. Tumors were ranked by support vector machine (SVM) and by cytologic severity. Nbs1 protein expression was assessed by quantitative immunohistochemistry in 49 primary uveal melanomas. Survival was assessed using Kaplan-Meier life-table analysis. Results: Expression of the Nijmegen breakage syndrome (NBS1) gene correlated strongly with SVM and cytologic tumor rankings (P < 0.0001). Further, immunohistochemistry expression of the Nbs1 protein correlated strongly with both SVM and cytologic rankings (P < 0.0001). The 6-year actuarial survival was 100% in patients with low immunohistochemistry expression of Nbs1 and 22% in those with high Nbs1 expression (P = 0.01). Conclusions: NBS1 is a strong predictor of uveal melanoma survival and potentially could be used as a clinical marker for guiding clinical management.

UR - http://www.scopus.com/inward/record.url?scp=16344362449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344362449&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-2054

DO - 10.1158/1078-0432.CCR-04-2054

M3 - Article

C2 - 15756009

AN - SCOPUS:16344362449

VL - 11

SP - 1849

EP - 1853

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -